期刊文献+

早期高危宫颈癌术后同期放化疗研究进展 被引量:14

Research advances in postoperative concurrent chemoradiotherapy (CCRT) for high-risk early stage cervical cancer
原文传递
导出
摘要 宫颈癌是常见妇科恶性肿瘤之一,位居全球2012年新发病例和死亡病例第四位。早期高危宫颈癌术后需要辅助治疗。术后同期放化疗较术后单纯放疗降低盆腔外复发率并提高生存率,较术后序贯放化疗延长中位生存时间和生存率。术后同期放化疗后巩固性化疗较术后单纯同期放化疗提高生存率。回顾性研究表明术后同期放化疗与术后单纯化疗疗效相当,但仍需进一步研究。影响术后同期放化疗疗效的因素主要包括化疗方案、放疗技术、手术与同期放化疗的时间间隔、多发盆腔淋巴结转移和盆腔淋巴结清扫个数等。术后同期放化疗不良反应主要包括血液学不良反应和胃肠道不良反应,其中血液学不良反应最常见。放疗技术的进步可改善不良反应发生率。 Cervical cancer is one of the most common gynecologic malignancy, ranking fnurth in new cases and deaths in 2012.High-risk early stage cervical cancer after operative need adjuvant treatment. Compared with postoperative radiotherapy alone, CCRT can reduce the pelvic recmxence rates and improve survival rates. And CCRT can extend median survival time and survival rates than sequential CRT after operative. CCRT plus consolidation chemotherapy may play a potential role in further improving survival outcomes for high-risk early stage cervical cancer patients compared with CCRT alone. Retrospective studies show that CCRT had equivalent effects with postoperative chemotherapy alone, but further research is needed. Factors influencing the efficacy of postoperative CCRT include chemotherapy regimens, radiotherapy technology, the interval time between surgery and CCRT, multiple pelvic lymph node metastasis and number of pelvic lymph node dissection. Toxicities mainly include hematologic and gastrointestinal toxicity. Hematologic toxicity is the most common. The incidenc, e of toxicity can be reduced by improving radiotherapy techniques.
出处 《中华放射肿瘤学杂志》 CSCD 北大核心 2017年第12期1470-1474,共5页 Chinese Journal of Radiation Oncology
基金 上海申康医院发展中心促进市级医院临床技能与临床创新能力三年行动计划(16CR3112B)
关键词 宫颈肿瘤 同期放化疗法 高危因素 不良反应 Cervical neoplasms/concurrent chemoradiotherapy High-risk Untoward effect
  • 相关文献

参考文献7

二级参考文献37

  • 1林仲秋,苏琛辉.宫颈癌术后辅助放疗[J].中国实用妇科与产科杂志,2006,22(8):568-569. 被引量:10
  • 2刘继红,黄鹤.放化疗综合治疗宫颈癌的评价[J].中国实用妇科与产科杂志,2006,22(8):629-631. 被引量:10
  • 3段迎春,胡平.宫颈癌的治疗进展[J].国外医学(妇产科学分册),2007,34(2):137-139. 被引量:31
  • 4Duenas-Gonzalez A, Cetina-Perez L, Onate-Ocana LF, et al. Multimodal treatment of locally advanced cervical cancer [ J ]. Arch Med Res, 2005,36(2) :129 -135. 被引量:1
  • 5Rose PG, Ali S, Watkins E, et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a gynecologic oncology group study [ J ]. J Clin Oncol, 2007,25 ( 19 ) : 2804 -2810. 被引量:1
  • 6Cox JD,Stetz J,Pajak TF.Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).Int J Radiation Oncology Biol Phys,1995,31(5):1341-1346. 被引量:1
  • 7Uno T,Isobe K,Yamamoto S,et al.Postoperative radiation therapy for carcinoma of the uterine cervix.Radiat Med,2006,24(2):91-97. 被引量:1
  • 8Ryu HS,Chun M,Chang KH,et al.Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high risk early stage cervical cancer patients.Gynecol Oncol,2005,96(2):490-495. 被引量:1
  • 9Duenas-Gonzalez A,Cetina-Perez L,Onate-Ocana LF,et al.Multimodal treatment of locally advanced cervical cancer.Arch Med Res,2005,36(2):129-135. 被引量:1
  • 10Rose PG,Ali S,Watkins E,et al.Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin,cisplatin -based combination chemotherapy,or hydroxyurea during pelvic irradiation for locally advanced cervical cancer:a gynecologic oncology group study.J Clin Oncol,2007,25(19):2804-2810. 被引量:1

共引文献40

同被引文献145

引证文献14

二级引证文献75

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部